Cargando…
Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
The reason why tumors generally have a modest or transient response to antiangiogenic therapy is not well understood. This poses a major challenge for sorafenib treatment of advanced hepatocellular carcinoma (HCC) where alternate therapies are lacking. We recently published a paper entitled “Co-opti...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124233/ https://www.ncbi.nlm.nih.gov/pubmed/27887628 http://dx.doi.org/10.1186/s40880-016-0162-7 |